Festival of Biologics Basel

Hill Describes Supercharged Biologics Market in China

January 11, 2021

Article

Lawrence A. Hill, PharmD, MBA, RPH, BCPS, provided an insider's view of the rapidly changing biologics and biosimilars market and regulatory structure in China.

Alvotech Scientific Officer Describes Company's Global Biosimilars Strategy

November 25, 2020

Article

Joseph E. McClellan, PhD, MBA, discussed navigation of regulatory hurdles as the company continues its quest to line up distribution partnership deals across the globe.

Prioritize Biosimilar Uptake in Europe, Conference Speaker Says

November 14, 2020

Article

In Europe, the pandemic has revealed problems within health care systems and the need to increase access to biosimilars and reform health care policies.

Expert Cautions on What to Expect From Real-World Biosimilar Evidence

November 4, 2020

Article

Expecting real-world evidence to confirm safety and efficacy of biosimilars is asking too much, Uwe Gudat, a pharmacovigilance expert from Fresenius Kabi, said at the Terrapinn Festival of Biologics Basel 2020.

Getting Orphan Biosimilars to Market at a Lower Price

November 3, 2020

Article

Biosimilar orphan drugs might not be cheaper than innovator orphan products, owing to multiple factors, but modifications to regulatory policy could change this, a presenter said at the Terrapinn Festival of Biologics Basel 2020.

Panelists Question Efficacy, Immunogenicity Studies for Biosimilars

November 3, 2020

Article

Certain biosimilar studies are performed out of an abundance of caution and good marketing sense, although science has leapfrogged the need for these trials, panelists said at the Terrapinn Festival of Biologics Basel 2020.